Oncology Institute (NASDAQ:TOI – Get Free Report) and Pono Capital Two (NASDAQ:PTWO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Volatility & Risk
Oncology Institute has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Pono Capital Two has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Oncology Institute and Pono Capital Two, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Oncology Institute | 0 | 0 | 1 | 0 | 3.00 |
Pono Capital Two | 0 | 0 | 0 | 0 | N/A |
Insider & Institutional Ownership
36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 60.8% of Pono Capital Two shares are held by institutional investors. 13.1% of Oncology Institute shares are held by insiders. Comparatively, 63.9% of Pono Capital Two shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Oncology Institute and Pono Capital Two’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Oncology Institute | -24.56% | -80.46% | -28.14% |
Pono Capital Two | N/A | -6.63% | 0.73% |
Earnings & Valuation
This table compares Oncology Institute and Pono Capital Two’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Oncology Institute | $324.24 million | 0.25 | -$83.07 million | ($0.92) | -1.16 |
Pono Capital Two | N/A | N/A | $340,000.00 | N/A | N/A |
Pono Capital Two has lower revenue, but higher earnings than Oncology Institute.
Summary
Pono Capital Two beats Oncology Institute on 6 of the 10 factors compared between the two stocks.
About Oncology Institute
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
About Pono Capital Two
Pono Capital Two, Inc. does not have any significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Pono Capital Two, Inc. was incorporated in 2022 and is based in Honolulu, Hawaii.
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.